Mary Reumuth
Director of Finance/CFO at KALA BIO, INC.
Net worth: 462 797 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eric Trachtenberg | M | 51 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 8 years |
| Howard Rosen | M | 66 | 10 years | |
| Jon Aron Olof Heimer | M | 57 | 4 years | |
| Mark Iwicki | M | 57 | 9 years | |
| Andrew Koven | M | 66 | 7 years | |
| Solange Bullukian | F | 59 | 3 years | |
| Carl Raimond | M | 53 | 4 years | |
| Fredrik Netzel | M | 55 | 5 years | |
| Johan Lund | M | 67 | 4 years | |
| Marjan Farid | M | 50 | 2 years | |
| Rickard El Tarzi | M | - | 5 years | |
| Gregory Perry | M | 63 | 6 years | |
| Todd Bazemore | M | 53 | 7 years | |
| Tommi Markus Unkuri | M | 44 | 5 years | |
| Robert Schueren | M | 62 | 2 years | |
| Mark Blumenkranz | M | 73 | 3 years | |
| Charles Myers | M | 70 | 3 years | |
| Jon Hindar | M | 68 | 3 years | |
| Nicolas Roelofs | M | 66 | 6 years | |
| Darius Kharabi | M | 45 | 3 years | |
| Anna Maria Marsell | F | 46 | 2 years | |
| Hannah Deresiewicz | F | - | - | |
| Gregory Moore | M | 59 | 1 years | |
| Oskar Hjelm | M | 39 | 4 years | |
| Ida Grundberg | M | 41 | 5 years | |
| Romulus Brazzell | M | 71 | 11 years | |
| Linda Ramirez-Eaves | F | 52 | 5 years | |
| Bruno Rossi | M | - | 1 years | |
| Johan Holmner | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Levine | M | 53 | - | |
| Janet Skogan Roemer | F | 68 | 6 years | |
| Robert A. Heft | M | 69 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 7 years |
| Alexander Fitzpatrick | M | 57 | 4 years | |
| Paulina Hill | M | 42 | 1 years | |
| Charles McDermott | M | 52 | 4 years | |
| Tina Nova | M | 70 | 1 years | |
| Raj Shah | M | 46 | 6 years | |
| Robert Paull | M | 47 | - | |
| Gregory Grunberg | M | 51 | 7 years | |
| Gerald M. Haines | M | 61 | 2 years | |
| Robert Langer | M | 74 | 9 years | |
| Gustavo Salem | M | 60 | 3 years | |
| Robert Tepper | M | 68 | 9 years | |
| John F. Dee | M | 66 | 5 years | |
| Steven Zhang | M | - | - | |
| Chen-Ming Yu | M | 50 | 1 years | |
| Vincent Kosewski | M | - | - | |
| Barbara Littlefield | F | 66 | 4 years | |
| James Patnoe | M | - | - | |
| Susan L. Coultas | M | - | 6 years | |
| John Miller | M | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 years |
| Kathleen McCann Kline | F | - | - | |
| Michele LaRussa | F | 54 | - | |
| Niranjan Kameswaran | M | - | - | |
| John R. Malloy | M | 65 | 2 years | |
| Stephen P. Toon | M | - | 2 years | |
| Gregory Powers | M | - | 2 years | |
| Julie Smith | F | 53 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 4 years |
| Geoffrey Peter Hazlewood | M | 73 | 7 years | |
| Thomas Schuetz | M | 63 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 5 years |
| Kevin Bitterman | M | 47 | - | |
| Kevin R. Bracken | M | 75 | - | |
| Fredric D. Price | M | 78 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 6 years |
| John A. McCarthy | M | 65 | 1 years | |
| Melvin I. Simon | M | 85 | 14 years | |
| Mark Leschly | M | 55 | 10 years | |
| William Baum | M | 79 | 13 years | |
| Simon B. Rich | M | 80 | 3 years | |
| Josiah Craver | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 45 | 65.22% |
| Sweden | 19 | 27.54% |
| Canada | 6 | 8.70% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mary Reumuth
- Personal Network
